Research Australia has responded to the Parliamentary Inquiry into the Approval Processes for New Drugs and Medical Technologies.
Opportunities exist to change our approval processes to benefit patients and better support research and development in Australia. Faster and more effective approval processes mean new medicines and technologies reach patients faster. Improving the environment for clinical trials enables Australian patients to benefit from the latest medicines and technologies developed overseas while also helping Australian health and medical research to flourish in a competitive and lucrative world market. Research Australia’s submission identifies some of these opportunities with the twin objectives of improving Australians’ health and prosperity.
Research Australia’s submission is available here.
The Committee is expected to hold public hearings in early 2021.
Research Australia has responded to the Queensland Competition Authority’s Draft Report of Queensland Government Industry Assistance. Research Australia supports the need for a clear rationale and strict criteria for Industry Assistance Programs but suggests that the proposed criteria need to be developed and applied more appropriately. In the case of health and medical research, the opportunity to improve the effectiveness and efficiency of the health care sector (with a saving to the Queensland Government) and to improve health and wellbeing need to be recognised as legitimate objectives of Government assistance. The submission highlights the complex interaction between public research funding and private sector involvement in the commercialisation of health and medical research, and points to some successful Queensland models that are worth supporting.
Industry Assistance in Queensland